SEARCH

SEARCH BY CITATION

References

  • 1
    Schmeiser HH, Stiborova M, Arlt VM. Chemical and molecular basis of the carcinogenicity of Aristolochia plants. Curr Opin Drug Dis Develop 2009; 12: 1418.
  • 2
    Debelle FD, Vanherweghem JL, Nortier JL. Aristolochic acid nephropathy: a worldwide problem. Kidney Int 2008; 74: 15869.
  • 3
    Nortier JL, Martinez MC, Schmeiser HH, Arlt VM, Bieler CA, Petein M, Depierreux MF, de Pauw L, Abramowicz D, Vereerstraeten P, Vanherweghem JL. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). New Engl J Med 2000; 342: 168692.
  • 4
    Lemy A, Wissing KM, Rorive S, Zlotta A, Roumeguere T, Muniz Martinez MC, Decaestecker C, Salmon I, Abramowicz D, Vanherweghem JL, Nortier J. Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: a case series with 15-year follow-up. Am J Kidney Dis 2008; 51: 4717.
  • 5
    Schmeiser HH, Bieler CA, Wiessler M, van Ypersele de Strihou C, Cosyns JP. Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res 1996; 56: 20258.
  • 6
    Bieler CA, Stiborova M, Wiessler M, Cosyns JP, van Ypersele de Strihou C, Schmeiser HH. 32P-post-labelling analysis of DNA adducts formed by aristolochic acid in tissues from patients with Chinese herbs nephropathy. Carcinogenesis 1997; 18: 10637.
  • 7
    Lord GM, Cook T, Arlt VM, Schmeiser HH, Williams G, Pusey CD. Urothelial malignant disease and Chinese herbal nephropathy. Lancet 2001; 358: 15156.
  • 8
    Arlt VM, Alunni-Perret V, Quatrehomme G, Ohayon P, Albano L, Gaid H, Michiels JF, Meyrier A, Cassuto E, Wiessler M, Schmeiser HH, Cosyns JP. Aristolochic acid (AA)-DNA adduct as marker of AA exposure and risk factor for AA nephropathy-associated cancer. Int J Cancer 2004; 111: 97780.
  • 9
    Lo SH, Wong KS, Arlt VM, Phillips DH, Lai CK, Poon WT, Chan CK, Mo KL, Chan KW, Chan A. Detection of Herba Aristolochia Mollissemae in a patient with unexplained nephropathy. Am J Kidney Dis 2005; 45: 40710.
  • 10
    Gold LS, Slone TH. Aristolochic acid, an herbal carcinogen, sold on the Web after FDA alert. New Engl J Med 2003; 349: 15767.
  • 11
    Grollman AP, Shibutani S, Moriya M, Miller F, Wu L, Moll U, Suzuki N, Fernandes A, Rosenquist T, Medverec Z, Jakovina K, Brdar B, et al. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci USA 2007; 104: 1212934.
  • 12
    Arlt VM, Stiborova M, vom Brocke J, Simoes ML, Lord GM, Nortier JL, Hollstein M, Phillips DH, Schmeiser HH. Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer. Carcinogenesis 2007; 28: 225361.
  • 13
    Cosyns JP, Jadoul M, Squifflet JP, de Plaen JF, Ferluga D, van Ypersele de Strihou C. Chinese herbs nephropathy: a clue to Balkan endemic nephropathy? Kidney Int 1994; 45: 16808.
  • 14
    Arlt VM, Ferluga D, Stiborova M, Pfohl-Leszkowicz A, Vukelic M, Ceovic S, Schmeiser HH, Cosyns JP. Is aristolochic acid a risk factor for Balkan endemic nephropathy-associated urothelial cancer? Int J Cancer 2002; 101: 5002.
  • 15
    Lord GM, Hollstein M, Arlt VM, Roufosse C, Pusey CD, Cook T, Schmeiser HH. DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy. Am J Kidney Dis 2004; 43: e117.
  • 16
    Arlt VM, Schmeiser HH, Pfeifer GP. Sequence-specific detection of aristolochic acid-DNA adducts in the human p53 gene by terminal transferase-dependent PCR. Carcinogenesis 2001; 22: 13340.
  • 17
    Liu Z, Hergenhahn M, Schmeiser HH, Wogan GN, Hong A, Hollstein M. Human tumor p53 mutations are selected for in mouse embryonic fibroblasts harboring a humanized p53 gene. Proc Natl Acad Sci USA 2004; 101: 29638.
  • 18
    Nedelko T, Arlt VM, Phillips DH, Hollstein M. TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy-associated tumours. Int J Cancer 2009; 124: 98790.
  • 19
    Stemmer K, Ellinger-Ziegelbauer H, Ahr HJ, Dietrich DR. Carcinogen-specific gene expression profiles in short-term treated Eker and wild-type rats indicative of pathways involved in renal tumorigenesis. Cancer Res 2007; 67: 405268.
  • 20
    Chen T, Guo L, Zhang L, Shi L, Fang H, Sun Y, Fuscoe JC, Mei N. Gene expression profiles distinguish the carcinogenic effects of aristolochic acid in target (Kidney) and non-target (Liver) tissues in rats. BMC Bioinform 2006; 7 ( Suppl 2): S20.
  • 21
    Simoes ML, Hockley SL, Schwerdtle T, da Costa GG, Schmeiser HH, Phillips DH, Arlt VM. Gene expression profiles modulated by the human carcinogen aristolochic acid I in human cancer cells and their dependence on TP53. Toxicol Appl Pharmacol 2008; 232: 8698.
  • 22
    Mengs U. Tumour induction in mice following exposure to aristolochic acid. Arch Toxicol 1988; 61: 5045.
  • 23
    Phillips DH, Arlt VM. The 32P-postlabeling assay for DNA adducts. Nat Protoc 2007; 2: 277281.
  • 24
    Hockley SL, Arlt VM, Brewer D, Giddings I, Phillips DH. Time- and concentration-dependent changes in gene expression induced by benzo(a)pyrene in two human cell lines, MCF-7 and HepG2. BMC Genomics 2006; 7: 260.
  • 25
    Hockley SL, Arlt VM, Jahnke G, Hartwig A, Giddings I, Phillips DH. Identification through microarray gene expression analysis of cellular responses to benzo(a)pyrene and its diol-epoxide that are dependent or independent of p53. Carcinogenesis 2008; 29: 20210.
  • 26
    Forrester LM, Henderson CJ, Glancey MJ, Back DJ, Park BK, Ball SE, Kitteringham NR, McLaren AW, Miles JS, Skett P, et al. Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochem J 1992; 281: 35968.
  • 27
    Kim S, Dere E, Burgoon LD, Chang CC, Zacharewski TR. Comparative analysis of AhR-mediated TCDD-elicited gene expression in human liver adult stem cells. Toxicol Sci 2009; 112: 22944.
  • 28
    vom Brocke J, Krais A, Whibley C, Hollstein MC, Schmeiser HH. The carcinogenic air pollutant 3-nitrobenzanthrone induces GC to TA transversion mutations in human p53 sequences. Mutagenesis 2009; 24: 1723.
  • 29
    Cosyns JP, Jadoul M, Squifflet JP, Wese FX, van Ypersele de Strihou C. Urothelial lesions in Chinese-herb nephropathy. Am J Kidney Dis 1999; 33: 10117.
  • 30
    Stiborova M, Frei E, Arlt VM, Schmeiser HH. Metabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy. Mutat Res 2008; 658: 5567.
  • 31
    Luo JL, Yang Q, Tong WM, Hergenhahn M, Wang ZQ, Hollstein M. Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool. Oncogene 2001; 20: 3208.
  • 32
    Jaworski M, Hailfinger S, Buchmann A, Hergenhahn M, Hollstein M, Ittrich C, Schwarz M. Human p53 knock-in (hupki) mice do not differ in liver tumor response from their counterparts with murine p53. Carcinogenesis 2005; 26: 182934.
  • 33
    Feldmeyer N, Schmeiser HH, Muehlbauer KR, Belharazem D, Knyazev Y, Nedelko T, Hollstein M. Further studies with a cell immortalization assay to investigate the mutation signature of aristolochic acid in human p53 sequences. Mutat Res 2006; 608: 1638.
  • 34
    Schmeiser HH, Janssen JW, Lyons J, Scherf HR, Pfau W, Buchmann A, Bartram CR, Wiessler M. Aristolochic acid activates ras genes in rat tumors at deoxyadenosine residues. Cancer Res 1990; 50: 54649.
  • 35
    Schmeiser HH, Scherf HR, Wiessler M. Activating mutations at codon 61 of the c-Ha-ras gene in thin-tissue sections of tumors induced by aristolochic acid in rats and mice. Cancer Lett 1991; 59: 13943.
  • 36
    Lebeau C, Arlt VM, Schmeiser HH, Boom A, Verroust PJ, Devuyst O, Beauwens R. Aristolochic acid impedes endocytosis and induces DNA adducts in proximal tubule cells. Kidney Int 2001; 60: 133242.
  • 37
    Lebeau C, Debelle FD, Arlt VM, Pozdzik A, de Prez EG, Phillips DH, Deschodt-Lanckman MM, Vanherweghem JL, Nortier JL. Early proximal tubule injury in experimental aristolochic acid nephropathy: functional and histological studies. Nephrol Dial Transplant 2005; 20: 232132.
  • 38
    Bakhiya N, Arlt VM, Bahn A, Burckhardt G, Phillips DH, Glatt H. Molecular evidence for an involvement of organic anion transporters (OATs) in aristolochic acid nephropathy. Toxicology 2009; 264: 749.
  • 39
    Jiang X, Wang X. Cytochrome C-mediated apoptosis. Annu Rev Biochem 2004; 73: 87106.
  • 40
    Pozdzik AA, Salmon IJ, Debelle FD, Decaestecker C, van den Branden C, Verbeelen D, Deschodt-Lanckman MM, Vanherweghem JL, Nortier JL. Aristolochic acid induces proximal tubule apoptosis and epithelial to mesenchymal transformation. Kidney Int 2008; 73: 595607.
  • 41
    Krones-Herzig A, Mittal S, Yule K, Liang H, English C, Urcis R, Soni T, Adamson ED, Mercola D. Early growth response 1 acts as a tumor suppressor in vivo and in vitro via regulation of p53. Cancer Res 2005; 65: 513343.
  • 42
    el-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994; 54: 116974.
  • 43
    Ohtsuka T, Jensen MR, Kim HG, Kim KT, Lee SW. The negative role of cyclin G in ATM-dependent p53 activation. Oncogene 2004; 23: 54058.
  • 44
    Luo JL, Tong WM, Yoon JH, Hergenhahn M, Koomagi R, Yang Q, Galendo D, Pfeifer GP, Wang ZQ, Hollstein M. UV-induced DNA damage and mutations in Hupki (human p53 knock-in) mice recapitulate p53 hotspot alterations in sun-exposed human skin. Cancer Res 2001; 61: 815863.
  • 45
    Pozdzik AA, Salmon IJ, Husson CP, Decaestecker C, Rogier E, Bourgeade MF, Deschodt-Lanckman MM, Vanherweghem JL, Nortier JL. Patterns of interstitial inflammation during the evolution of renal injury in experimental aristolochic acid nephropathy. Nephrol Dial Transplant 2008; 23: 248091.
  • 46
    Goetz CA, Baldwin AS. NF-kappaB pathways in the immune system: control of the germinal center reaction. Immunol Res 2008; 41: 23347.
  • 47
    Schumm K, Rocha S, Caamano J, Perkins ND. Regulation of p53 tumour suppressor target gene expression by the p52 NF-kappaB subunit. EMBO J 2006; 25: 482032.
  • 48
    Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431: 4616.
  • 49
    Goodrich DW. The retinoblastoma tumor-suppressor gene, the exception that proves the rule. Oncogene 2006; 25: 523343.
  • 50
    Chang HR, Lian JD, Lo CW, Chang YC, Yang MY, Wang CJ. Induction of urothelial proliferation in rats by aristolochic acid through cell cycle progression via activation of cyclin D1/cdk4 and cyclin E/cdk2. Food Chem Toxicol 2006; 44: 2835.
  • 51
    Datta A, Sen J, Hagen J, Korgaonkar CK, Caffrey M, Quelle DE, Hughes DE, Ackerson TJ, Costa RH, Raychaudhuri P. ARF directly binds DP1: interaction with DP1 coincides with the G1 arrest function of ARF. Mol Cell Biol 2005; 25: 802436.
  • 52
    Gallagher SJ, Kefford RF, Rizos H. The ARF tumour suppressor. Int J Biochem Cell Biol 2006; 38: 163741.
  • 53
    Schulz WA, Jankevicius F, Gerharz CD, Kushima M, van Roeyen C, Bultel H, Gobell P, Schmitz-Drager BJ. Predictive value of molecular alterations for the prognosis of urothelial carcinoma. Cancer Detect Prev 1998; 22: 4229.
  • 54
    Habuchi T, Kinoshita H, Yamada H, Kakehi Y, Ogawa O, Wu WJ, Takahashi R, Sugiyama T, Yoshida O. Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification. J Natl Cancer Inst 1994; 86: 13315.
  • 55
    Grimm MO, Jurgens B, Schulz WA, Decken K, Makri D, Schmitz-Drager BJ. Inactivation of tumor suppressor genes and deregulation of the c-myc gene in urothelial cancer cell lines. Urol Res 1995; 23: 293300.
  • 56
    Christoph F, Schmidt B, Schmitz-Drager BJ, Schulz WA. Over-expression and amplification of the c-myc gene in human urothelial carcinoma. Int J Cancer 1999; 84: 16973.
  • 57
    Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev 2008; 8: 97690.
  • 58
    Milde-Langosch K. The Fos family of transcription factors and their role in tumourigenesis. Eur J Cancer 2005; 41: 244961.
  • 59
    Schulz WA. Understanding urothelial carcinoma through cancer pathways. Int J Cancer 2006; 119: 15138.